SCHEMBL6466280

SCHEMBL6466280

COc1cc2c(C)nc(Nc3nc(OC(=O)C(F)(F)F)c4cccc(OC)c4n3)nc2cc1F

nearest known ligand 0.37

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.37
ABCG2 Q9UNQ0 1/20 0.36
ADORA2A P29274 3/20 0.35
POLB P06746 2/20 0.35
GAA P10253 1/20 0.35
SMN1; SMN2 Q16637 3/20 0.35
ALDH1A1 P00352 2/20 0.35
PKM P14618 1/20 0.35
CREBBP Q92793 1/20 0.35
MAPT P10636 3/20 0.35
TP53 P04637 2/20 0.35
NPSR1 Q6W5P4 1/20 0.34
KDM4E B2RXH2 1/20 0.34
HPGD P15428 1/20 0.34
HSD17B10 Q99714 1/20 0.34
MEN1 O00255 1/20 0.34
RAD52 P43351 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6468599 0.90 ADORA2A (0.37) KMT2AABCG2ADORA2APOLBSMN1; SMN2
SCHEMBL6467193 0.90 ABCG2 (0.40) KMT2AABCG2POLBGAASMN1; SMN2
SCHEMBL6467879 0.90 KMT2A (0.45) KMT2AABCG2POLBGAASMN1; SMN2
SCHEMBL6469862 0.89 KMT2A (0.35) KMT2AABCG2ADORA2APOLBGAA
SCHEMBL6469759 0.88 KMT2A (0.37) KMT2AABCG2POLBSMN1; SMN2ALDH1A1
SCHEMBL6468647 0.87 ABCG2 (0.38) KMT2AABCG2POLBGAASMN1; SMN2
SCHEMBL6468661 0.87 BRAF (0.39) ADORA2A
SCHEMBL6468667 0.87 TP53 (0.40) KMT2AABCG2POLBGAAMAPT
SCHEMBL6467851 0.86 MAPT (0.36) KMT2AABCG2POLBGAAALDH1A1
SCHEMBL6467457 0.85 ALDH1A1 (0.36) KMT2AADORA2APOLBGAASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050124562-A1 Bis-quinazoline compounds for the treatment of bacterial infections REPLIDYNE, INC. 2005-06-09 US claimed
WO-2005030131-A2 BIS-QUINAZOLINE COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS REPLIDYNE, INC (US) 2005-04-07 WO claimed
US-20050124562-A1 Bis-quinazoline compounds for the treatment of bacterial infections REPLIDYNE, INC. 2005-06-09 US disclosed
WO-2005030131-A2 BIS-QUINAZOLINE COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS REPLIDYNE, INC (US) 2005-04-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050124562-A1 Bis-quinazoline compounds for the treatment of bacterial infections POLI, POLK, POLB KMT2A 2156/4885ABCG2 1526/4885ADORA2A 4250/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.